Status:
RECRUITING
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Collaborating Sponsors:
KU Leuven
Conditions:
Lung Diseases, Interstitial
NSCLC
Eligibility:
All Genders
18-120 years
Brief Summary
The main goal of this prospective non-interventional exploratory study is to characterize the tumor micro-environment of advanced NSCLC in single-cell resolution, prior to immune checkpoint blockade e...
Detailed Description
The investigators will collect tumor biopsies from 70 st.IV NSCLC patients before start of treatment with immune checkpoint inhibitors. These biopsies are taken during a medically required routine pro...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Adult M/F/X (\>= 18 years)
- Histologically and clinically confirmed diagnosis of non-small cell lung cancer (according to IASLC Staging Handbook in Thoracic Oncology v7)
- Patients receiving first-line treatment per guidelines
- Not included in other clinical trials
- Signed informed consent form
- Exclusion criteria:
- • Collected material not suitable for further processing in this study (e.g. bad quality). This decision will be made in consultation with a lab technician and/or bio-informatician, specialized in single-cell analysis.
Exclusion
Key Trial Info
Start Date :
February 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04807114
Start Date
February 1 2020
End Date
January 31 2025
Last Update
July 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitaire Ziekenhuizen Leuven
Leuven, Belgium, 3000